Nevertheless, the combination of these two imaging modalities into PSMA PET/MRI revealed high diagnostic accuracy in the staging of PCa and the ability to change clinical treatment decisions in a significant number of patients, including a switch to the AS approach [20]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.